For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pacira BioSciences Inc’s stock clocked out at $25.75, up 0.35% from its previous closing price of $25.66. In other words, the price has increased by $0.35 from its previous closing price. On the day, 1.14 million shares were traded. PCRX stock price reached its highest trading level at $26.925 during the session, while it also had its lowest trading level at $24.915.
Ratios:
To gain a deeper understanding of PCRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.14. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 2.25. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when SLONIN JONATHAN sold 879 shares for $18.40 per share. The transaction valued at 16,174 led to the insider holds 93,444 shares of the business.
SLONIN JONATHAN bought 879 shares of PCRX for $16,174 on Jan 06 ’25. On Dec 13 ’24, another insider, GAUGLER DARYL, who serves as the Chief Operating Officer of the company, sold 500 shares for $19.76 each. As a result, the insider received 9,880 and left with 115,200 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1188959872 and an Enterprise Value of 1379573888. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 1.985 whereas that against EBITDA is 7.749.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.79, which has changed by -0.20988035 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $34.01, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 32.46%, while the 200-Day Moving Average is calculated to be 24.14%.
Shares Statistics:
It appears that PCRX traded 757.66K shares on average per day over the past three months and 942230 shares per day over the past ten days. A total of 46.15M shares are outstanding, with a floating share count of 44.70M. Insiders hold about 3.19% of the company’s shares, while institutions hold 112.14% stake in the company. Shares short for PCRX as of 1736899200 were 5444817 with a Short Ratio of 7.19, compared to 1734048000 on 4750188. Therefore, it implies a Short% of Shares Outstanding of 5444817 and a Short% of Float of 17.169999999999998.
